Loading clinical trials...

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension) | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT04270942

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type ...

Lead sponsor: Provention Bio, a Sanofi Company•8 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 3

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137 · Diabetes Mellitus, Type 1

RECRUITING

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

NCT06807190 · Diabetes Mellitus, Type 1

RECRUITING

A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar

NCT07160816 · Diabetes Mellitus, Type 1

RECRUITING

Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery

NCT07478211 · Diabetes Mellitus, Type 1, Energy Metabolism

RECRUITINGPhase 3

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

NCT04786262 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 12, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment6

Start dateFeb 2020

Last updatedFeb 12, 2025

Condition

Diabetes Mellitus, Type 1

Locations shown

Barbara Davis Center for Diabetes Site Number : 04

Aurora, Colorado

Clinical Site

Aurora, Colorado

Yale University School of Medicine Site Number : 01

New Haven, Connecticut

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar

Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Trial snapshot

Condition

Locations shown

For caregivers